Wiener klinische Wochenschrift, Journal Year: 2024, Volume and Issue: 136(21-22), P. 587 - 589
Published: Oct. 22, 2024
Language: Английский
Respiratory Research, Journal Year: 2025, Volume and Issue: 26(1)
Published: Jan. 18, 2025
Post-COVID-19 respiratory sequelae often involve lung damage, which is called residual abnormalities, and potentially lead to chronic issues. The adaptive immune response, involving T-cells B-cells, plays a critical role in pathogen control, inflammation, tissue repair. However, the link between dysregulation development of abnormalities remains unclear. 109 patients discharged with after COVID-19 were followed for 12 months divided as full recovery (FRG, n = 88) persistent (PLAG, 21). Cell profiling analysis was done using flow cytometry at 24 h not antigen-specific vitro stimulation. Plasma or supernatant levels IFN-g, IL-4, IL-10, IgM, IgG assessed, 10 (5 FRG, 5 PLAG) randomly selected detailed cell phenotyping functional peripheral blood mononuclear cells cytometry. Compared FRG group, PLAG exhibited an increase unswitched (p 0.0159) decreased double-negative activated B-cells 0.0317), systemic IL-10 lower, displayed reduced frequency total impaired spontaneous IgM 0.0357) 0.0079) release culture. Regarding T-cells, showed reduction effector memory CD4 + TEMRA following Notably, group also higher frequencies central Th2 (GATA3+) response activation than 0.0079). Patients post-critical exhibit B-cell function, increased activation. These imbalances may contribute ongoing dysfunction warrant further investigation potential mechanism abnormalities. Larger studies are necessary confirm these findings.
Language: Английский
Citations
0
Archives of Dermatological Research, Journal Year: 2025, Volume and Issue: 317(1)
Published: Jan. 24, 2025
Language: Английский
Citations
0
Allergy, Journal Year: 2025, Volume and Issue: unknown
Published: March 3, 2025
ABSTRACT Background COVID‐19 continues to be a major global health challenge. Inhaled siRNA‐based MIR 19 has been shown reduce the time clinical improvement in patients hospitalized with moderate COVID‐19. Methods We conducted an open‐label, randomized, controlled multicenter phase 2b‐3 trial (NCT05783206) evaluating safety and efficacy of inhaled siR‐7‐EM/KK‐46 (MIR 19) (5.55 mg/day) comparison standard care (control group) outpatients mild ( N = 492 for each group). The primary endpoint was proportion who developed or severe by 28th day randomization. Results Moderate course disease detected 14 (2.85%) 34 (6.91%) mg) therapy groups, respectively (the difference proportions −4.107% [95% CI: −7.28% −1.03%] p 0.002)). Adverse events (AE) were reported 77 (15.65%) from group, while group AEs registered 100 (20.33%) patients. No severe, treatment‐related observed group. Conclusions siR‐7‐EM/KK‐46, SARS‐CoV‐2‐specific RNAi‐based drug, well‐tolerated significantly decreased progression moderate/severe
Language: Английский
Citations
0
Allergy, Journal Year: 2025, Volume and Issue: unknown
Published: March 14, 2025
ABSTRACT An estimated 10% of coronavirus disease (COVID‐19) survivors suffer from persisting symptoms referred to as long COVID (LC), a condition for which approved treatment options are still lacking. This systematic review (PROSPERO: CRD42024499281) aimed explore the pathophysiological mechanisms underlying LC and potential treatable traits across symptom‐based phenotypes. We included studies with primary data, written in English, focusing on omics analyses human samples patients persistent at least 3 months. Our search PubMed Embase, conducted January 8, 2024, identified 642 studies, 29 met inclusion criteria after full‐text assessment. The risk bias was evaluated using Joanna Briggs Institute appraisal tool. synthesis including genomics, transcriptomics, proteomics, metabolomics, metagenomics, revealed common findings associated fatigue, cardiovascular, pulmonary, neurological, gastrointestinal Key mitochondrial dysfunction, dysregulated microRNAs pulmonary tissue impairment, blood–brain barrier disruption, coagulopathy, vascular microbiome disturbances, microbial‐derived metabolite production inflammation. Limitations include cross‐study heterogeneity variability sampling methods. emphasizes complexity need further longitudinal omics‐integrated advance development biomarkers targeted treatments.
Language: Английский
Citations
0
Published: Jan. 1, 2025
Citations
0
Egyptian Journal of Bronchology, Journal Year: 2025, Volume and Issue: 19(1)
Published: April 12, 2025
Abstract Background Community-acquired pneumonia (CAP) remains among the primary cause of morbidity and mortality in children globally. Despite improved treatment guidelines, still there is a vast increase incidence complications linked to CAP. Identifying various risk factors predisposing development complicated community-acquired (CCAP) paves way verify determine new approaches for prevention, early diagnosis, effective management such complications. Aim To identify elucidate that predispose diagnosed with develop local pulmonary (complicated pneumonia) our Egyptian community. Methods One-hundred pediatric cases CAP were involved case–control study, where classified into 2 groups depending on absence (41 cases) or presence (59 Data demographics, medical history, physical examination, laboratory radiological findings collected analyzed. Logistic regression analysis was utilized predict enhancing population. Results Median age studied patients 3.5 years ranging between 0.5 13 years. Gender wise, 55 (55%) population males. Patients living urban areas 47 (47%) patients. High-grade fever reported 91% patients, 63% them received antipyretic form NSAID. Previous COVID-19 infection positive 29% while 26% had previous hospital admission pneumonia. below 5th percentile weight height represented 19%. showed following complication starting over 2.5 more likely complications, an odds ratio (OR) 95% confidence interval (95% CI) 11.875 (3.626–38.885) ( P = 0.000). Urban residence emerged as another critical factor, 61.0% being dwellers OR 4.269 (1.794–10.155) 0.001) respectively. Clinical history 5.868 (1.152–29.883) 0.033), NSAID use 2.822 (1.219–6.532) 0.015), past 2.888 (1.095–7.616) 0.028) prevalent cases. Additionally, CCAP often CI ) 4.713 (1.274–17.434) 0.020) anemia 3.420 (1.158–10.103) 0.041) thrombocytosis 4.889 (1.935–12.351) 0.023). Conclusion The study highlights including following: than years, areas, percentile, fever, NSAID, weaning breastfeeding, exposure environmental tobacco smoke (ETS), daycare center attendance, COVID-19, hemoglobin level equal less 8.9 g/dl, thrombocytosis. Early identification targeted interventions prevention these will lower children.
Language: Английский
Citations
0
Vaccine, Journal Year: 2025, Volume and Issue: 56, P. 127171 - 127171
Published: May 1, 2025
Language: Английский
Citations
0
BioMedInformatics, Journal Year: 2025, Volume and Issue: 5(2), P. 26 - 26
Published: May 9, 2025
COVID-19 has caused millions of deaths around the world. The respiratory system is main target this disease, but it also been reported to attack central nervous system, creating a neuroinflammatory environment with release proinflammatory cytokines. There are several studies suggesting possible relationship between Alzheimer’s disease and COVID-19. Therefore, in study, machine learning microarray analysis was performed identify key genes that may be associated disease. dataset identified as GSE177477, containing 47 samples. A bioconductor oligo package RStudio (version 4.3.3) used process normalize data. Subsequently, one-way ANOVA obtain differentially expressed genes. We decision tree generation classify study 1856 Three trees were generated where three (DNAJC16, TREM1, UCP2) differentiated patients. best obtained an accuracy 72.34%, sensitivity 72.34% specificity 86.17%. involved processes like those such inflammation process, amyloid pathologies, related type 2 diabetes mellitus.
Language: Английский
Citations
0
Viruses, Journal Year: 2024, Volume and Issue: 17(1), P. 41 - 41
Published: Dec. 30, 2024
Background: During the acute phase of COVID-19, a number immunological abnormalities have been reported, but few studies longitudinally analyzed specific subsets peripheral blood lymphocytes. Methods: In this observational, prospective, and longitudinal study, adult patients developing pneumonia during COVID-19 pandemic followed up for 12 months. Peripheral lymphocyte were assessed (with focus on memory markers) at 6 time points after disease onset until Results: A total 76 with (characterized by prevalently interstitial pattern lung inflammation) hospital admission (who completed 12-month follow-up period) recruited in study. They divided into two groups, namely positive (n = 31) negative 45) SARS-CoV-2 PCR test. phase, general immunophenotyping profile was comparable most parameters between these except B cells. When T cells according to expression markers, significant decrease naïve CD8+ observed SARS-CoV-2-positive group phase. Notably, aspect maintained period least 9 Conclusions: seems be associated lower compared virus. This alteration can persist convalescent
Language: Английский
Citations
1
Authorea (Authorea), Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 1, 2024
According to the existing facts, COVID-19 is prone infection for a long time, and attacks immune system, immunity of population continues decline. Decreased has limit (immune deficiency), which can cause opportunistic infections, tumors other problems. In addition, myocarditis neurological problems should not be ignored. this paper, we guess that virus invasion cells result interaction proteins on membrane. Epidemiology predicts symptoms related are follow by biased normal distribution, at bottom, further outbreaks will occur in future. We also mentioned measures taken now (Promote detection immunity, such as CD4 cell counts).
Language: Английский
Citations
0